Is Zimmer Biomet (ZBH) a risky stock?
As of July 21, 2026, Clavix grades Zimmer Biomet (ZBH) B+ for risk, a composite score of 79 out of 100 on an A+ to F scale, which puts ZBH in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind ZBH's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ZBH scores on each, as of July 21, 2026.
What's moving ZBH's risk right now
Company-specific signals Clavix flags behind ZBH's current grade, drawn from recent news and filings as of July 21, 2026.
The appointment signals Zimmer Biomet's continued focus on the Asia Pacific region as a growth market, bringing in an experienced medtech leader to potentially accelerate regional…
A new regional leader for Asia Pacific suggests ZBH may be prioritizing execution and growth in a key international market, which could impact the pace of revenue expansion in the…
The leadership change signals ZBH's renewed focus on the Asia Pacific market, a key growth region for medtech, potentially accelerating regional revenue expansion and competitive…
What a B+ grade means
On the Clavix A+ to F scale, ZBH's composite of 79 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ZBH or any security. Grades are risk indicators, not predictions of return. Data may be delayed.